Table 2.

Drugs selected for analysis

allopurinol	ciprofloxacin	fluoxetine	metformin	sibutramine
amiloride	clozapine	furosemide	methadone	sildenafil
amiodarone	co-trimoxazole	gentamycin	methotrexate	spironolactone
atenolol	cyclosporine	glibenclamide	nevirapine	sumatriptan
azathioprine	diclofenac	hydrochlorothiazide	omeprazole	theophylline
bromocriptine	digoxin	imipramine	pethidine	tramadol
captopril	disulfiram	itraconazole	phenobarbital	valproate
carbamazepine	erythromycin	lamotrigine	phenytoin	verapamil
cefamandole	ethinyloestradiol	lithium	pravastatin	vincristine
cimetidine	flecainide	isocarboxazid*	ritonavir	warfarin

^*There was no nonselective monoamine-oxidase inhibitor (MAOI) marketed in all countries. Isocarboxazid is marketed in the UK and in the USA but not in France. However, as all interactions are common to all nonselective MAOIs in Vidal, it was assumed that these interactions were also relevant for isocarboxazid.